CSPC Pharmaceutical Group Limited has announced a strategic research collaboration agreement with AstraZeneca, a global leader in biopharmaceuticals, to discover and develop novel oral small molecule candidates. The agreement will utilize CSPC's AI-driven, dual-engine efficient drug discovery platform to identify promising small molecules targeting multiple diseases. AstraZeneca will have the option to exclusively license the pre-clinical candidates for development, manufacturing, and commercialization worldwide. CSPC will receive an upfront payment of $110 million, with potential additional payments totaling up to $1,620 million for development milestones and $3,600 million for sales milestones, along with possible royalties based on annual net sales.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.